United Therapeutics Corp. (UTHR)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about United Therapeutics Corp. (UTHR)
Company Performance

Current Price

as of Oct 11, 2024

$358.22

P/E Ratio

16.28

Market Cap

$15.76B

Description

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Metrics

Overview

  • HQSilver Spring, MD
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerUTHR
  • Price$358.22+1.10%

Trading Information

  • Market Cap$15.76B
  • Float98.25%
  • Average Daily Volume (1m)344,323
  • Average Daily Volume (3m)424,406
  • EPS$23.11

Company

  • Revenue$2.62B
  • Rev Growth (1yr)19.85%
  • Net Income$278.10M
  • Gross Margin89.12%
  • EBITDA Margin47.36%
  • EBITDA$338.60M
  • EV$12.66B
  • EV/Revenue4.84
  • P/E16.28
  • P/S6.43
  • P/B2.76
Documents
SEC Filings
8-K (2024-07-31)
8-K (2024-06-27)
8-K (2024-05-01)
8-K (2024-03-29)
8-K (2024-03-25)
8-K (2024-02-27)
8-K (2024-02-21)
8-K (2023-12-20)
8-K (2023-11-29)
8-K (2023-11-01)
8-K (2023-08-02)
8-K (2023-07-24)
8-K (2023-06-28)
8-K (2023-05-03)
8-K (2023-04-21)
8-K (2023-03-31)
8-K (2023-02-22)
8-K (2023-01-09)
10-Q (2024-07-31)
10-Q (2024-05-01)
10-Q (2023-11-01)
10-Q (2023-08-02)
10-Q (2023-05-03)
10-K (2024-02-21)
10-K (2023-02-22)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-01)
Earnings Report (2023-08-02)
Factset
Factset Business Description
Factset Street Account
United Therapeutics reports Q3 EPS $5.38 vs FactSet $5.10 [10 est, $4.01-6.06] ($222.86, 0.00) (2023-11-01T10:03:44Z)
United Therapeutics further extends term of Adcirca license agreement with Lilly through 31-Dec-26 - 8-K ($230.39, 0.00) (2023-11-29T11:10:29Z)
StreetAccount Metrics Recap - United Therapeutics Q3 Earnings ($222.86, 0.00) (2023-11-01T10:05:11Z)
StreetAccount Earnings Call Q&A Summary: United Therapeutics Q3 ($ 217.29, -5.57) (2023-11-01T14:07:15Z)
StreetAccount Consensus Metrics Preview - United Therapeutics Q3 Earnings ($224.04, -0.46) (2023-10-26T19:54:49Z)
Wikipedia
United_Therapeutics_Corp.